Search Results - "Strupp, C"

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification by Nachtkamp, K., Strupp, C., Vukelja, M., Kasprzak, A., Haase, D., Ganster, C., Hildebrandt, B., Betz, B., Giagounidis, A., Aul, C., Blum, S., Hofmann, W. K., Pfeilstöcker, M., Valent, P., Lübbert, M., Seidl, M., Rudelius, M., Stauder, R., Krieger, O., Götze, K. S., Bobak, J., Kündgen, A., Schulz, F., Dietrich, S., Kobbe, G., Gattermann, N., Germing, U.

Get full text

Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias by Schuler, E, Schroeder, M, Neukirchen, J, Strupp, C, Xicoy, B, Kündgen, A, Hildebrandt, B, Haas, R, Gattermann, N, Germing, U

“…Highlights • We showed that proliferative CMML types do worse as compared to dysplastic types. • Progression rates of CMML with <5% blasts are lower as…”
Get full text

Assessing in vitro dermal absorption of dry residues of agrochemical sprays using human skin within OECD TG 428 by Aggarwal, M., Fisher, P., Kluxen, F.M., Maas, W., Morgan, N., Parr-Dobrzanski, R., Strupp, C., Wiemann, C.

“…We describe a novel experimental method that mimics exposure to dried agrochemical residues on contact surfaces during re-entry into crops. It includes the…”
Get full text

Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes by Strupp, C, Aul, C, Germing, U

Get full text

Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML by Schuler, E., Frank, F., Hildebrandt, B., Betz, B., Strupp, C., Rudelius, M., Aul, C., Schroeder, T., Gattermann, N., Haas, R., Germing, U.

“…•MDS patients with monocytic marrow proliferation have a more CMML-like phenotyp.•MDS patients with monocytic marrow proliferation have a more CMML-like…”
Get full text

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid by KUENDGEN, Andrea, STRUPP, Corinna, AIVADO, Manuel, BERNHARDT, Alf, HILDEBRANDT, Barbara, HAAS, Rainer, GERMING, Ulrich, GATTERMANN, Norbert

“…Valproic acid (VPA) has been shown to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in the differentiation…”
Get full text

Thalidomide for the treatment of patients with myelodysplastic syndromes by STRUPP, C, GERMING, U, AIVADO, M, MISGELD, E, HAAS, R, GATTERMANN, N

“…We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients…”
Get full text

P772: PROGNOSTIC IMPACT OF DISEASE‐RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS) by Lesch, C., Kündgen, A., Nachtkamp, K., Kasprzak, A., Strupp, C., Rudelius, M., Gattermann, N., Kobbe, G., Hildebrandt, B., Germing, U.

Get full text

Assessment of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption by Aggarwal, M., Battalora, M., Fisher, P., Hüser, A., Parr-Dobrzanski, R., Soufi, M., Mostert, V., Strupp, C., Whalley, P., Wiemann, C., Billington, R.

“…•A robust data set from 190 in vitro human dermal absorption studies is evaluated.•Defaults of 6% for liquids, 2% for solids and 30% for spray dilutions are…”
Get full text

Transfusion Need and Comorbidities are Independent Prognostic Parameters in Low Risk MDS Patients by Neukirchen, J, Strupp, C, Schuler, E, Zimmermann, E, Kündgen, A, Haas, R, Germing, U

Get full text

I-005 WHO 2013 by Germing, U, Strupp, C

Get full text

P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY by Schulz, F., Kostova, J., Hildebrandt, B., Nachtkamp, K., Strupp, C., Gattermann, N., Lübbert, M., Blum, S., Parmentier, S., Götze, K., Lipke, J., Beier, F., Hofmann, W.‐K., Germing, U.

Get full text

Myelodysplastic Syndromes Showing Slight Monocytic Marrow Proliferation Are Prone to Progress to CMML by Schuler, E, Frank, F, Betz, B, Hildebrandt, B, Aul, C, Strupp, C, Schroeder, T, Haas, R, Germing, U

Get full text

W. Otterspeer (ed.), De hand van Huizinga by C. Strupp

Get full text

Assessment of an extended dataset of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption by Aggarwal, M., Fisher, P., Hüser, A., Kluxen, F.M., Parr-Dobrzanski, R., Soufi, M., Strupp, C., Wiemann, C., Billington, R.

“…•A robust data set from 295 in vitro human dermal absorption studies is evaluated.•Defaults of 6% for liquids, 2% for solids and 30% for spray dilutions are…”
Get full text

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) by GERMING, U, HILDEBRANDT, B, STAUDE, R, GIAGOUNIDIS, A. A. N, STRUPP, C, KÜNDGEN, A, MUELLER, T, HAAS, R, GATTERMANN, N, AUL, C, PFEILSTÖCKER, M, NÖSSLINGER, T, VALENT, P, FONATSCH, C, LÜBBERT, M, HAASE, D, STEIDL, C, KRIEGER, O

“…The international prognostic scoring system (IPSS) is considered the gold standard for risk assessment in primary myelodysplastic syndromes (MDS). This score…”
Get full text

Patients with IPSS-R Intermediate Risk can be Separated Into Three Risk Groups by Nachtkamp, K, Reykowski, T, Hildebrandt, B, Baldus, S, Rudelius, M, Neukirchen, J, Kündgen, A, Strupp, C, Schroeder, T, Haas, R, Germing, U

Get full text

317 ASXL1 MUTATION IS ASSOCIATED TO LOWER PLATELET COUNTS AND DECREASED BONE MARROW CELLULARITY IN MDS by Schemenau, J, Betz, B, Hildebrandt, B, Baldus, S, Kündgen, A, Neukirchen, J, Strupp, C, Haas, R, Germing, U

Get full text

240 DYSPLASIAS REVISITED – CONSIDERATIONS FOR A MULTIDIMENSIONAL APPROACH TO HETEROGENEITY OF MDS: DATA ON 1979 PATIENTS FROM THE GERMAN AUSTRIAN DATA BASE by Pfeilstöcker, M, Tuechler, H, Nachtkamp, K, Platzbecker, U, Schönmetzler, A, Sperr, W, Stauder, R, Strupp, C, Valent, P, Germing, U

Get full text

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup by Giagounidis, A A N, Germing, U, Strupp, C, Hildebrandt, B, Heinsch, M, Aul, C

“…The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a…”
Get full text